Blogs About Health Care
We found 6 Blog entries on this topic; most recently published at the top.
In the Era of PRISM, ‘Knowing and Showing’ on Human Rights
Aditi Mohapatra, Associate Director, Advisory Services Dunstan Allison Hope, Managing Director, Advisory Services
As public scrutiny of U.S. government surveillance tactics grows, BSR has been reflecting on the corporate responsibility and ethics issues at stake—and how these issues extend beyond the information and communications technology sector. Read more →
Women’s World Banking: What Women’s Empowerment Means to Me
Mary Ellen Iskenderian, President and CEO, Women’s World Banking
In a guest blog, we hear from Women's World Banking on how public-private partnerships, in-depth market research, and financial products designed for the specific needs of women can contribute to women's empowerment. Read more →
Is the Health Care Industry Really Failing at CSR?
Mark Little, Director, Healthcare, Advisory Services
Fast Company seems to think so, at least according to a recent blog by Brian Jackson, who asserts that while almost every other sector has found a way to pursue CSR efforts, health care companies have failed, despite several opportunities to pursue sustainable options. But I’d suggest that the analysis put forward by Jackson is too cursory to support his ultimate conclusion that “the long-term viability of health care entities is at risk.” Read more →
The Pharmaceutical Industry’s Sustainable Supply Chain
Mark Little, Director, Healthcare, Advisory Services
The Pharmaceutical industry is making great strides in a pre-competitive collaboration to improve sustainability in its supply chain. Since inception of the Pharmaceutical Supply Chain Initiative (PSCI) in 2006, membership has nearly doubled to 14 companies, a recognition that “Big Pharma” sees a business case in working together to develop a common set of environmental, social, and ethical supplier standards. Read more →
The Future of Nanotechnology for Pharma
Mark Little, Director, Healthcare, Advisory Services
Nanotechnology has supported breakthrough innovation across many industries yet has been met with mixed stakeholder views. Recently, BSR hosted a member event for pharmaceutical companies to discuss nanotechnology applications in the healthcare sector and to consider the related CSR implications. It was an educational experience to be sure with lectures from two science luminaries: Dr. David Hollinshead, Director Science Policy, AstraZeneca and Mike King, an expert from MATTER—a U.K.-based organization focused on stakeholder engagements surrounding new technology applications and their implications for civil society. Compared to the most material issues pharmaceutical companies face—access to medicines, product quality, supply chain, ethics in sales and marketing—nanotechnology is often treated as a horizon issue. While there are some stakeholders with questions around nanotechnology, we learned that the objective science behind nanotechnology stands to bring pharmaceutical companies more opportunities than risks. Nano means “small”—and the simple fact is that smaller particles have larger surface area and are therefore more quickly absorbed into the blood stream. As Dr. David Hollinshead put it, “Nanomedicines are most likely better medicines.” And already, many pharmaceutical companies have begun utilizing nanotechnology to improve drug delivery and targeting. In oncology, for example, nanomedicines are being tested for their ability to reach cell targets that have otherwise eluded more conventional medicines. Yet, the nature of this scientific advancement remains surrounded by “unknown unknowns.” And there is a need for companies—in the pharma sector and beyond—to be proactive in the management and communication of this technology. From MATTER’s “Walking with Stakeholders” project, we know that lack of information is itself a source of distrust among stakeholders. As King put it, “It’s not so much that nano is an issue today, but it’s worth managing and watching closely if only to avoid a situation like that in which Monsanto found itself with GM (genetically modified foods).” So for pharmaceutical companies, the question is not, “Is nano a stakeholder concern?” but rather, “What do we need to learn, and then what do we need to show our stakeholders to gain their trust?” Read more →
More Blogs About Health Care
Filter Health Care
- 6 Blog Entries
- 21 BSR Insight articles
- No BSR Voices podcasts at this time
- 3 Reports
- 2 Case Studies
- No Sustainable Investment in China articles at this time
- Show All Health Care Entries Sorted by Date
